Stevanato Group S.p.A. (STVN) Insider Stocchi Sells 6,586 Shares
Chief Business Strategy Officer Mauro Stocchi sold shares in Stevanato Group on June 9.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mauro Stocchi, Chief Business Strategy Officer at Stevanato Group S.p.A. ($STVN), sold 6,586 shares on June 9, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $STVN is down 8.4% after 1 week, up 9.5% after 1 month and up 4.8% to date (from the $18.03 close on Jun 9, 2026).
STVN
Stevanato Group S.p.A.
Key Points
- Mauro Stocchi, Chief Business Strategy Officer at Stevanato Group, sold 6,586 shares on June 9, 2026.
- Stevanato Group's stock on the NYSE traded near $18.39 on Friday, with a market cap of $5.02 billion and a P/E ratio of 31.71.
- TD Cowen initiated coverage with a 'buy' rating and a $25 target on June 16, 2026.
Get $STVN trade alerts by text
We text you when insiders, Congress or big funds trade $STVN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Stevanato Group S.p.A. alert may contain errors. Disclosures
Mauro Stocchi, the Chief Business Strategy Officer at Stevanato Group S.p.A. (NYSE:STVN), sold 6,586 shares of the company on June 9, 2026. The transaction did not occur under a pre-planned Rule 10b5-1 trading plan.
Stevanato Group S.p.A. Stock Down 4.8%
Shares of NYSE:STVN traded near $18.39 on Friday. Stevanato Group, a leader in the healthcare sector, has a market capitalization of approximately $5.02 billion. The company's price-to-earnings ratio stands at 31.71, with a forward P/E of 21.95, indicating investor expectations for future earnings growth. The stock's 52-week range is between $12.89 and $28.00, with a 50-day moving average of $17.39 and a 200-day moving average of $19.57.
Insider Buying and Selling at Stevanato Group S.p.A.
In addition to Mauro Stocchi's sale, several other insiders have been active. On June 15, 2026, insiders Flynn Karen, Federici William, Balachandran Madhavan, and Morel Donald Jr. each sold 1,493 shares at an average price of $17.09. Meanwhile, on June 12, William Federici bought 4,975 shares, and Marco Dal Lago, the Chief Financial Officer, acquired 2,356 shares.
Analysts Set New Price Targets
Analyst activity has been robust around Stevanato Group. On June 16, 2026, TD Cowen initiated coverage with a 'buy' rating and a price target of $25. Earlier, on June 2, Wolfe Research assumed coverage with a 'buy' rating and a $21 target. The consensus among analysts is a 'buy' recommendation, with an average price target of $24.45.
About Stevanato Group
Stevanato Group S.p.A. designs and produces medical instruments and supplies, serving the biopharmaceutical and healthcare industries globally. Based in Piombino Dese, Italy, the company offers solutions such as pre-fillable syringes, drug delivery systems, and diagnostic tools. Founded in 1949, it employs over 6,000 people and is led by CEO Mr. Franco Stevanato.
Bottom Line
Mauro Stocchi's recent sale of shares in Stevanato Group comes amid active insider trading and a series of new analyst ratings. Investors keep a close eye on such insider activities and analyst opinions as potential indicators of a company's future performance. However, it's important to remember that these insider transactions are disclosed after the fact and may not reflect current positions.
Related Filing Alerts
Source: Mauro Stocchi's Form 4 filing on $STVN (Jun 9, 2026). Find the original filing: STVN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts